Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Drops By 6.6%

Esperion Therapeutics, Inc. (NASDAQ:ESPR) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 31,250,000 shares, a decline of 6.6% from the October 31st total of 33,460,000 shares. Approximately 16.0% of the company’s stock are short sold. Based on an average daily volume of 3,820,000 shares, the days-to-cover ratio is currently 8.2 days.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Needham & Company LLC lowered their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday. Finally, StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors have recently modified their holdings of the business. BOKF NA purchased a new stake in shares of Esperion Therapeutics during the second quarter worth $26,000. Traphagen Investment Advisors LLC acquired a new position in Esperion Therapeutics during the third quarter worth about $27,000. Xponance Inc. acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at approximately $28,000. Sivia Capital Partners LLC purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at $44,000. Finally, National Bank of Canada FI lifted its stake in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,225 shares during the period. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Stock Performance

Shares of ESPR stock traded up $0.15 during mid-day trading on Tuesday, hitting $3.25. 5,484,148 shares of the stock traded hands, compared to its average volume of 6,157,205. Esperion Therapeutics has a 52-week low of $1.35 and a 52-week high of $3.44. The stock’s fifty day moving average is $2.14 and its two-hundred day moving average is $2.17.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.